In an era when opinion often trumps evidence in public health issues, it's time to support and invest in evidence-based medicine to protect the public from dangerous, poorly informed beliefs.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Drug companies funded more than 116,000 educational events for doctors over four years. Now you can find out exactly which companies footed the bills and how much they paid.
More of us are labelled as sick with the constantly changing diagnostic cut-offs for diseases. Now an international expert panel has drafted a list of things to consider before setting new thresholds.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
We have barely begun to tap into the pharmaceutical potential of the most diverse animals of all.
Children's cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Feel-good fudges designed to boost staff morale are giving way to tangible projects which can be reported to shareholders.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company's products.
What will happen to immigration, wages and the economy has been discussed at length. But the price of drugs may also be affected.
The sources of the opioid epidemic are complex, but one powerful motivator has been the pursuit of profit.
The lack of transparency and accountability found in the hedge fund world is increasingly finding a home in the pharmaceutical sector, where more people care.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can't always protect us from harm.
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
This project offers the tantalising possibility that plants containing drugs, such as agents to treat HIV, could be farmed on a small scale at low cost by communities that need them most.
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Five new European studies say dementia occurrence is stable or falling. Our panic may have been unnecessary.
Ever wonder how much it costs to develop a new drug? The Tufts Center for the Study of Drug Development estimates US$2.6 billion. But how accurate is this figure?